OSE Immunotherapeutics aims to bring scientific and clinical innovation to patients who need restoring their immune disorders

Immunotherapy has very different clinical applications in the fields of immuno-oncology, autoimmune diseases and transplantation. But in terms of immune response, the same immunological targets and immune cells may be involved during the mechanisms of stimulation and tolerance. The understanding of these targets and of their individual roles enable the identification of optimized stimulation or regulation therapies, according to the immune function to be restored in a selected pathology
In immuno-oncology, autoimmune diseases and transplantation, the medical need for new therapeutic appproaches remains significant. Through its development programs, OSE Immunotherapeutics addresses patients suffering from seemingly distinct diseases which, in fact, involve the same key cells playing major roles, namely effector and regulator cells. For these patients, the targeted therapeutic response is the restoration of their immune functions.

Metastatic cancers : There are currently a lack of therapeutic solutions for metastatic cancers. During the last two American Society of Clinical Oncology (ASCO) congresses in 2014 and 2015, the topic of immunotherapy was presented as a real hope of stabilization and even remission for some patients. “Strategies using the immune system against the tumor are considered a huge scientific breakthrough,” noted the prestigious journal, Science (December 2013). “It’s not about targeting the tumor only, anymore, but to arm the immune system”.
View Pathologies

Autoimmune diseases : Their occurrence makes this group a major health issue, just as cardiovascular or cancer diseases. Autoimmune diseases are chronic, often they affect young patients and require long term treatments.
View Pathologies

Transplantations and marrow transplants : In recent years, a variety of new immunosuppressant medications have been approved, widening the scope of existing therapeutic options. Nevertheless, all current protocols require the patient to take immunosuppression medication on a daily basis and for the rest of his life, in order to minimize the risk of chronic rejection, which can take months or years to manifest, clinically. For example, in 15 years, the six-year survival rate of renal transplant has increased from 66% to 80%. However, the rate of graft failure due to a chronic rejection and to nephrotoxicity of immunosuppressors (5% per year) has not improved over the same time period. Therefore, the need for new and innovative approaches still exists.
View Pathologies

OSE Immunotherapeutics : a growth strategy based on internal product development and strategic industry partnerships

OSE Immunotherapeutics aims to become a leading international player in the field of immunotherapy.
The company has a portfolio of advanced immunotherapy products in Phases 2 and 3, as well as other promising immunotherapy candidates in preclinical development.

The company’s growth strategy is based on the development of advanced products for immune activation and regulation, the development of products targeting new key receptors of immune restoration, and on the synergy fostered by the combination of agonist and/or antagonist products, the development of new generation checkpoints inhibitors to achieve major therapeutic innovations.

In immuno-oncology:

  • Tedopi® (OSE-2101), a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology
    Registration Phase 3 trial in advanced NSCLC in EU/US in HLA A2+ patients; follow-up of patients already included ongoing after temporary pause of new patient accrual end of June 2017 – Orphan Status in the US.
    A Phase 2 with Tedopi® in combination with an immune checkpoint inhibitor is planned in locally advanced and metastatic pancreatic cancer, in collaboration with GERCOR, an oncology cooperative group of clinical research.
  • OSE-172 (Effi-DEM), a new generation checkpoint inhibitor targeting the SIRP-α receptor – In preclinical development for several cancer models.
  • OSE-703 (Effi-3), cytotoxic monoclonal antibody against the alpha chain of IL-7R – Under a research collaboration with Memorial Sloan Kettering Cancer Center, New York.

In auto-immune diseases and transplantation:

  • FR104, CD28-antagonist in immunotherapy – Phase 1 trial completed – For the treatment of autoimmune diseases and for use with transplantation – Licensed to Janssen Biotech Inc. to pursue clinical development.
  • OSE-127 (Effi-7), interleukin receptor-7 antagonist – In preclinical development for inflammatory bowel diseases and other autoimmune diseases. License option agreement with Servier for the development and commercialization.

In terms of R&D, the company’s objective is to select the most innovative drug candidates to enter preclinical and clinical development, in order to develop activation and regulation products of immune response.

OSE Immunotherapeutics’ program development is carried out by internal teams supported by a network of international immunotherapy experts, and through strategic industry partnerships, initiated at various product development stages.

View Partnerships

Thanks to its advanced clinical programs and innovative drug candidates in immuno-oncology, autoimmune diseases and transplantation (View product portfolio), OSE Immunotherapeutics is leveraging its capabilities to sign key license agreements (business development) – just one strategy that will help to ensure the company’s future development.

Such partnerships are aimed at developing and/or commercializing the company’s drug candidates, extending their use to other applications, and distributing them to specific geographies.